November 7th 2025
Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.
Cardiometabolic Diseases and Dementia Risk Show Dose-dependent Relationship in Large Twin Study
January 13th 2023For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.